Translational molecular imaging and drug development in multiple sclerosis.

Area of Science:

• Neuroscience
• Radiology
• Immunology

Background:

• Multiple sclerosis (MS) is a chronic CNS neurodegenerative disorder affecting young adults, characterized by demyelination.
• Diagnosis relies on clinical data, MRI lesions, and cerebrospinal fluid oligoclonal bands.
• Conventional MRI is crucial for MS diagnosis and monitoring, but advanced MRI methods are emerging.

Purpose of the Study:

• To review the challenges and opportunities in translational molecular imaging for multiple sclerosis.
• To highlight molecular concepts for diagnostic imaging, patient stratification, and therapy monitoring in MS.
• To explore future developments in MS molecular imaging for improved patient care.

Main Methods:

• Review of current and emerging molecular imaging techniques, including Positron Emission Tomography (PET).
• Discussion of myelin-targeted probes, ligands for TSPO and CB2R to visualize neuroinflammation (microglial activation), and synaptic integrity tracers.
• Analysis of how these techniques can complement conventional MRI in MS diagnosis and management.

Main Results:

• PET imaging shows significant potential to advance MS diagnosis and management.
• Myelin-targeted probes are under clinical evaluation for MS diagnosis and therapy monitoring.
• TSPO and CB2R ligands visualize neuroinflammation, while other tracers assess synaptic integrity in MS.

Conclusions:

• Molecular imaging, especially PET, offers promising avenues for diagnosing and monitoring MS.
• Targeting myelin, neuroinflammation, and synaptic integrity provides new insights into MS pathophysiology.
• Advancements in molecular imaging are crucial for personalized patient care and drug development in MS.